Oriheal Pimotone Plus 2.5mg Tablet for Dogs and Cats
Inclusive of all taxes
Product Details
| Product type | Oral Tablets |
| Volume / Quantity | Typically available in packs of 10 Tablets (or multi-strip boxes under Rx rules) |
| Target Species | Canines and Felines (Dogs and cats diagnosed with early to moderate cardiovascular disease, valvular insufficiency, or cardiac enlargement) |
| Common Use Case | Long-term therapeutic management of clinical congestive heart failure (CHF) stemming from Myxomatous Mitral Valve Disease (MMVD) or Dilated Cardiomyopathy (DCM); reduction of peripheral and systemic blood vessel congestion; delaying heart failure progression in pre-clinical DCM or mitral valve disease; and managing blood pressure to alleviate fatigue, chronic coughing, and exercise intolerance. |
Oriheal Pimotone Plus 2.5mg is an advanced, prescription-only dual-action veterinary cardiovascular medication meticulously formulated to manage early to moderate congestive heart failure (CHF) and structural heart diseases in dogs and cats. This specialized formula delivers a synergistic, fixed-dose combination of Pimobendan (2.5mg) and Benazepril Hydrochloride (5mg) designed to optimize cardiac output while lowering blood vessel strain in smaller to medium-sized pets.
Pimobendan functions as a premier "inodilator" by acting as a calcium sensitizer to directly increase myocardial contractility (positive inotropy) while selectively inhibiting the phosphodiesterase III (PDE3) enzyme to dilate blood vessels without significantly raising heart tissue oxygen demand. Working alongside it, Benazepril Hydrochloride operates as a potent Angiotensin-Converting Enzyme (ACE) inhibitor that suppresses the renin-angiotensin-aldosterone system (RAAS), preventing the conversion of angiotensin I to angiotensin II to relax blood vessels and lower systemic blood pressure. Together, this dual mechanism counteracts conditions like Myxomatous Mitral Valve Disease (MMVD) and Dilated Cardiomyopathy (DCM), easing fluid buildup (pulmonary edema) and noticeably lessening clinical symptoms like coughing, breathlessness, and lethargy.